YOU MATTER.
Upcoming Events
Thirteenth European International Kidney Cancer Symposium
April 27 - April 28Kidney Cancer Association 2018 Patient Meeting
September 22 - September 23Seventeenth International Kidney Cancer Symposium
November 2 - November 3
Publications
0
%
5-Year Survival Rate Percentage increase from 2007 through 2013
0
Estimated new cases in the US, this year
0
Estimated Deaths in the US, this year
0
People are living with kidney and renal pelvis cancer, according to NCI SEER data from 2014
Evaluate your treatment options and make decisions
From the Pressroom
Videos: 2017 Kidney Cancer Association Patient & Survivor Conference
Videos from KCA patient and survivor conference that held in North Carolina on December 9th, 2017 is now available online.
FDA Grants Breakthrough Designation for Avelumab in Combination with INLYTA in Advanced Renal Cell Carcinoma
A combination approach with an immunotherapy, whose activity may complement existing agents such as INLYTA, has the potential to improve outcomes for patients with advanced renal cancer…
FDA Approves Adjuvant Sunitinib for High-Risk RCC
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.
YOU MATTER.
WE CARE.
YOU ARE NOT ALONE.
Kidney Cancer Association
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. It is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers.
Immunotherapy Combo of Opdivo and Yervoy Wins FDA's OK for Kidney Cancer
Read about the U.S. Food and Drug Administration approving a combination of Opdivo and Yervoy for advanced kidney cancer.
immuno-oncologynews.com
Kidney cancer: New DNA test can measure whether tumor might be fatal
Hundreds of people with kidney cancer could be spared surgery with a DNA test that can identify whether tumours are likely to be highly aggressive or relatively harmless, scientists say. … While some kinds of kidney cancer grow and metastasise around the body with lethal speed, others do not appea...
geneticliteracyproject.org
Effects of A 2 Weeks on/1 Week Off Sunitinib Schedule in Metastatic RCC
For this phase 2 study (ClinicalTrials.gov Identifier: NCT02060370), researchers evaluated the safety and efficacy of sunitinib 50 mg administered on a 2/1 schedule among 59 patients with metastatic RCC. Patients were able to adjust dose and schedule depending on AEs.
cancertherapyadvisor.com
15 hours ago
FDA Approves Opdivo-Yervoy Combo for Advanced #KidneyCancer https://t.co/7ckqm8pfH4
FDA Approves Opdivo-Yervoy Combo for Advanced #KidneyCancer https://t.co/7ckqm8pfH4
FDA Approves Opdivo-Yervoy Combo for Advanced #KidneyCancer https://t.co/7ckqm8pfH4
— Kidney Cancer (@KidneyCancer) April 25, 2018
21 hours ago
FDA Approves Opdivo-Yervoy Combo for Advanced #KidneyCancer
https://t.co/7ckqm8pfH4 https://t.co/hqoTnlDZ2y
FDA Approves Opdivo-Yervoy Combo for Advanced #KidneyCancer
https://t.co/7ckqm8pfH4 https://t.co/hqoTnlDZ2y
FDA Approves Opdivo-Yervoy Combo for Advanced #KidneyCancer https://t.co/7ckqm8pfH4 pic.twitter.com/hqoTnlDZ2y
— Kidney Cancer (@KidneyCancer) April 25, 2018
1 day ago
The latest Cancer News Daily! https://t.co/i25gOV4jEp Thanks to @EASLnews @NottsCC @isnotpolitics #cancer #lungcancer
The latest Cancer News Daily! https://t.co/i25gOV4jEp Thanks to @EASLnews @NottsCC @isnotpolitics #cancer #lungcancer
The latest Cancer News Daily! https://t.co/i25gOV4jEp Thanks to @EASLnews @NottsCC @isnotpolitics #cancer #lungcancer
— Kidney Cancer (@KidneyCancer) April 25, 2018